Cor Vasa 2012, 54(7-8):419-423

Kombinační léčba k dosažení cílových hodnot LDL cholesterolu

Prof. MUDr. Richard Češka, CSc.
Centrum preventivní kardiologie, III. interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha

Keywords: Apolipoprotein B; Ezetimib; LDL cholesterol; Niacin; Pryskyřice; Statiny

Published: July 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češka R. Kombinační léčba k dosažení cílových hodnot LDL cholesterolu. Cor Vasa. 2012;54(7-8):419-423.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hradec J, Bultas J, Kmínek A, et al. Jak se léčí statiny v České republice? Výsledky průzkumu STEP. Cor Vasa 2011;53:527-34. Go to original source...
    2. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomised controlled trial. JAMA 2004;291:1071-80. Go to original source... Go to PubMed...
    3. Ballantyne M, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J 2005;149:464-73. Go to original source... Go to PubMed...
    4. Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94. Go to original source... Go to PubMed...
    5. Kastelein J. What future for combination therapies? Int J Clin Pract Suppl 2003;(134):45-50.
    6. Stone N. Combination therapy: its rationale and the role of ezetimibe. Eur Heart J Suppl 2002;4:J19-J22. Go to original source...
    7. SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010;160:785-94. Go to original source... Go to PubMed...
    8. Rossebo AB, Pedersen TR, Boman K, et al., for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56. Go to original source... Go to PubMed...
    9. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81. Go to original source...
    10. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. Go to original source...
    11. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98. Go to original source... Go to PubMed...
    12. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15. Go to original source... Go to PubMed...

    Return to the content